Intra-Cellular Therapies (ITCI) PT Cut to $29 at Leerink Partners Amid ITI-007 Failure
- Shares jump on tech boost; fragile yen on intervention watch
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Oil prices climb amid US stocks decline, Middle East conflict
- Yen on the brink, but Tesla pulls back
- Dollar recovers from PMI slump, yen closes in on 155 per dollar
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Intra-Cellular Therapies (ITCI) PT Cut to $22 at Piper Jaffray; Thinks Trial Not Drug a Failure
September 29, 2016 6:47 AM EDTPiper Jaffray analyst Charles Duncan slashed his price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $22.00 (from $57.00) after the company announced that its second P3 in schizophrenia failed to meet the primary endpoint, with 007 generating improvements in the PANSS that were over-shadowed by a higher-than-expected placebo response. The analyst maintained... More
Intra-Cellular Therapies (ITCI) Sinks 69% as Trading Resumes
September 28, 2016 4:33 PM EDTIntra-Cellular Therapies (NASDAQ: ITCI) sinks 68.7% as trading resumes following trial failure.
... MoreIntra-Cellular Therapies (ITCI) Announces ITI-007 Phase 3 Missed Primary Endpoint in Schizophrenia
September 28, 2016 4:03 PM EDTIntra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced top-line results from the second Phase 3 clinical trial (Study 302) of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated from placebo on the primary endpoint, change from baseline on the Positive and Negative Syndrome Scale (PANSS) total score, in the pre-defined patient population. The active control, risperidone, did separate from placebo. In this trial, ITI-007 was statistically significantly better than risperidone on key safety and tolerability parameters and exhibited a safety profile similar to placebo. This replicates the... More